Ariad's chronic myeloid leukemia drug ponatinib (marketed under the brand name Iclusig) had excellent clinical trial results, and was approved by the Food and Drug Administration ahead of schedule in mid-December. Why, then, did shares of Ariad drop around 14% last month despite this good news? Isn't an FDA approval usually good news for biotech stocks?

Our analysts Max Macaluso and Brenton Flynn break down this story in the following video and also discuss what to watch at Ariad in 2013.


What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article What Hurt Ariad's Shares in December? originally appeared on Fool.com.

Brenton FlynnMax Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Asset Allocation

Learn the most important step in structuring an investment portfolio.

View Course »

Investment Strategies

What's your investing game plan?

View Course »

Add a Comment

*0 / 3000 Character Maximum